HomeComparePGHY vs PFE

PGHY vs PFE: Dividend Comparison 2026

PGHY yields 7.20% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $17.4K in total portfolio value· pulled ahead in Year 10
10 years
PGHY
PGHY
● Live price
7.20%
Share price
$19.55
Annual div
$1.41
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.2K
Annual income
$1,136.38
Full PGHY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — PGHY vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPGHYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PGHY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PGHY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PGHY
Annual income on $10K today (after 15% tax)
$611.75/yr
After 10yr DRIP, annual income (after tax)
$965.92/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,353.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PGHY + PFE for your $10,000?

PGHY: 50%PFE: 50%
100% PFE50/50100% PGHY
Portfolio after 10yr
$40.9K
Annual income
$13,697.55/yr
Blended yield
33.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

PGHY
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PGHY buys
0
PFE buys
0
No recent congressional trades found for PGHY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPGHYPFE
Forward yield7.20%6.13%
Annual dividend / share$1.41$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$32.2K$49.6K
Annual income after 10y$1,136.38$26,258.71
Total dividends collected$9.3K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PGHY vs PFE ($10,000, DRIP)

YearPGHY PortfolioPGHY Income/yrPFE PortfolioPFE Income/yrGap
1$11,420$719.70$9,153$693.39+$2.3KPGHY
2$12,987$768.11$8,593$849.25+$4.4KPGHY
3$14,713$816.40$8,336$1,066.78+$6.4KPGHY
4$16,607$864.36$8,437$1,384.80+$8.2KPGHY
5$18,681$911.82$9,013$1,875.40+$9.7KPGHY
6$20,948$958.61$10,306$2,680.72+$10.6KPGHY
7$23,418$1,004.58$12,820$4,101.38+$10.6KPGHY
8$26,107$1,049.60$17,673$6,826.70+$8.4KPGHY
9$29,028$1,093.57$27,543$12,591.86+$1.5KPGHY
10← crossover$32,197$1,136.38$49,560$26,258.71$17.4KPFE

PGHY vs PFE: Complete Analysis 2026

PGHYStock

The Invesco Global ex-US High Yield Corporate Bond ETF (Fund) is based on the ICE USD Global High Yield Excluding US Issuers Constrained Index (Index). The Fund generally will invest at least 80% of its total assets in the components that comprise the Index, all of which are denominated in US dollars. The Index is composed of U.S. dollar denominated below investment grade corporate debt publicly issued in the U.S. domestic and eurobond markets by non-U.S. issuers. The Fund does not purchase all of the securities in the Index; instead, the Fund utilizes a “sampling” methodology to seek to achieve its investment objective. The Fund and the Index are rebalanced on the last calendar day of each month.

Full PGHY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this PGHY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PGHY vs SCHDPGHY vs JEPIPGHY vs OPGHY vs KOPGHY vs MAINPGHY vs JNJPGHY vs MRKPGHY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.